viewGoPro Inc

GoPro's bottom line turns negative

GoPro? More like GoBroke, as the wearable camera maker had a shocking third quarter

Hero4 mountable camera
A less than heroic performance

Fallen glamor stock GoPro Inc (NASDAQ:GPRO) disappointed its diminishing band of fans again with its third quarter earnings statement last night.

Shares in the wearable camera pioneer, trading as high as US$87 just over two years ago, tumbled 15.8% to US$10.05 in pre-market trading as the company's bottom line turned negative.

The company reported an adjusted post-tax loss of US$84.3mln for the three months to the end of September, versus a profit of US$36.6mln in the same period of 2015.

Revenue slumped 39.9% to US$240.6mln from US$400.3mln as the company botched the launch of its Hero5 camera and its Karma drone device.

Heading into the peak trading period for the company, GoPro predicted revenue in the fourth quarter would be US$625mln, give or take US$25mln.

The company has had problems ramping up production of its new products, and while stockists have run down stocks of legacy products in expectation of receiving shed-loads of the new stuff, the company has been unable to restock its retail channels.

“Furthermore, we anticipate difficulty catching up to meet forecasted [sic] demand during the fourth quarter,” revealed Nicholas Woodman, the company's founder and chief executive officer.

Despite the slide into the red, Woodman remained defiant, predicting a return to profitability in 2017 on the back of a projected double-digit percentage increase in revenue.

Quick facts: GoPro Inc

Price: 3.795 USD

Market: NASDAQ
Market Cap: $592 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: TRACON Pharmaceuticals reveals its low-cost drug development...

TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer tells Proactive the biotechnology company ended 2019 with cash, cash equivalents and short-term investments of $16.4 million. Theuer explains despite engaging in five different clinical trials, three of the five company's clinical trials...

12 hours, 28 minutes ago

2 min read